Key facts
- It has raised $2.0M; the latest was Later Stage VC in Jun 2024.
- Notable investors include Techstars, Capital Factory, Trousdale Ventures, Drive Capital, Next Sequence — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for NeuroX1
- ·The full record, as it builds
Funding rounds
No funding rounds for NeuroX1 are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NeuroX1
Developer a computational neuroscience and drug discovery engine designed to identify degenerative disorders of the brain. The company's platform identifies drivers of disease and generative chemistry to produce compounds for those diseases, primarily neurodegenerative to conduct data analytics, design drugs, screen molecules in silicon, and design small molecules most likely to have clinical success, enabling the healthcare sector to improve novel disease identification.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2021
- Employees
- 4
- Website
- neurox1.com/
- Ownership
- Privately Held (backing)
NeuroX1 doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NeuroX1 shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NeuroX1 in its N-PORT filings yet. We sweep new filings monthly.